• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant.

作者信息

King Alexandra

出版信息

Nat Rev Cardiol. 2010 Nov;7(11):602. doi: 10.1038/nrcardio.2010.148.

DOI:10.1038/nrcardio.2010.148
PMID:21080606
Abstract
摘要

相似文献

1
Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant.预防：神经精神方面的不良反应表明利莫那班已走到尽头。
Nat Rev Cardiol. 2010 Nov;7(11):602. doi: 10.1038/nrcardio.2010.148.
2
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.利莫那班预防心血管事件（CRESCENDO）：一项随机、多中心、安慰剂对照试验。
Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.
3
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.用于戒烟的1型大麻素受体拮抗剂（利莫那班）
Cochrane Database Syst Rev. 2007 Jul 18(3):CD005353. doi: 10.1002/14651858.CD005353.pub2.
4
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.用于戒烟的1型大麻素受体拮抗剂（利莫那班）
Cochrane Database Syst Rev. 2007 Oct 17(4):CD005353. doi: 10.1002/14651858.CD005353.pub3.
5
An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.利莫那班在随机对照试验中的代谢作用概述：其他大麻素 1 型受体阻滞剂在肥胖症中的应用潜力。
J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x.
6
Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.大麻素受体1阻滞剂利莫那班（SR 141716）用于治疗酒精依赖：一项安慰剂对照双盲试验的结果
J Clin Psychopharmacol. 2008 Jun;28(3):317-24. doi: 10.1097/JCP.0b013e318172b8bc.
7
A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.一项关于在利莫那班基础上加用尼古丁贴片戒烟的随机对照试验：疗效、安全性及体重增加情况
Addiction. 2009 Feb;104(2):266-76. doi: 10.1111/j.1360-0443.2008.02454.x.
8
Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.利莫那班对普拉德-威利综合征成年患者的精神方面不良反应
Eur J Med Genet. 2011 Jan-Feb;54(1):14-8. doi: 10.1016/j.ejmg.2010.09.015. Epub 2010 Oct 20.
9
Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.关于利莫那班治疗不良事件的系统评价和荟萃分析：其在肝病学中潜在应用的考量
BMC Gastroenterol. 2009 Oct 9;9:75. doi: 10.1186/1471-230X-9-75.
10
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.利莫那班对腹型肥胖合并冠状动脉疾病患者动脉粥样硬化进展的影响：STRADIVARIUS随机对照试验
JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

引用本文的文献

1
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.司美格鲁肽与安慰剂在SELECT研究中的安全性概况：一项随机对照试验
Obesity (Silver Spring). 2025 Mar;33(3):452-462. doi: 10.1002/oby.24222. Epub 2025 Feb 13.
2
Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides.三文鱼源生物活性肽对 GLP-1 和 GIP 受体的体外激活及胰岛细胞保护的初步探索
Mar Drugs. 2024 Oct 30;22(11):490. doi: 10.3390/md22110490.
3
Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice.

本文引用的文献

1
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.利莫那班预防心血管事件（CRESCENDO）：一项随机、多中心、安慰剂对照试验。
Lancet. 2010 Aug 14;376(9740):517-23. doi: 10.1016/S0140-6736(10)60935-X.
外周受限 CB1 受体反向激动剂 JD5037 治疗加剧 MDR2 缺陷型小鼠的肝损伤。
Cells. 2024 Jun 25;13(13):1101. doi: 10.3390/cells13131101.
4
Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1.针对大麻素受体CB1的FDA批准化合物的计算和实验性药物重新利用
Pharmaceuticals (Basel). 2023 Dec 2;16(12):1678. doi: 10.3390/ph16121678.
5
Cannabis Use Is Associated With Depression Severity and Suicidality in the National Comorbidity Survey-Adolescent Supplement.在《国家共病调查青少年补充调查》中，大麻使用与抑郁严重程度和自杀倾向有关。
JAACAP Open. 2023 Jun;1(1):24-35. doi: 10.1016/j.jaacop.2023.02.002. Epub 2023 Mar 3.
6
Convulsant doses of abused synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA and JWH-018 do not elicit electroencephalographic (EEG) seizures in male mice.滥用的合成大麻素受体激动剂 AB-PINACA、5F-AB-PINACA、5F-ADB-PINACA 和 JWH-018 的致惊厥剂量在雄性小鼠中不会引起脑电图 (EEG) 发作。
Psychopharmacology (Berl). 2022 Oct;239(10):3237-3248. doi: 10.1007/s00213-022-06205-6. Epub 2022 Aug 6.
7
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.从阿斯利康药物研发管线的命运中吸取的教训：一个五维框架。
Nat Rev Drug Discov. 2014 Jun;13(6):419-31. doi: 10.1038/nrd4309. Epub 2014 May 16.
8
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.靶向敲除 GPR26 会通过激活下丘脑 AMPK 导致过度摄食和肥胖。
PLoS One. 2012;7(7):e40764. doi: 10.1371/journal.pone.0040764. Epub 2012 Jul 16.